Research and Practice Funding

March 31, 2025

Completed

Title: Data for Health Gender Equity CORE. Principal Investigator: Michelle Kaufman, PhD, MA. Role: Project Manager (2023)

Major Goal: The Gender Equity Core will serve as a knowledge center and resource hub for all partners and countries in the Data for Health Initiative to center gender equity in their work. Award: Bloomberg Philanthropies, BP-2019-67099

Total award amount including indirect costs: $2,500,000; Project dates: 07/01/2021-03/31/2025

Title: Immunologic Determinants of Age-Related Macular Degeneration (AMD) Project-Continuation. Principal Investigator: Douglas A. Jabs, MD, MBA. Role: Research Manager (2021-2023)

Major Goal: The major goal of this project is to evaluate the roles of immunosenescence and systemic inflammation in the development of AMD. 

Award: NIH NEI R01EY025093. Total award amount including indirect costs: $1,833,904; Project dates: 09/01/2021-08/31/2025

Title: Johns Hopkins Institute for Clinical and Translational Research (ICTR)—UL Portion. Principal Investigator: Daniel E. Ford, MD, MPH.

Role: Research Navigator, Trial Innovation Unit (TIU) (2021-2023)

Major Goal: The primary goal of the ICTR is to accelerate the improvement in the health of Maryland by utilizing team-driven science to translate basic discoveries into new intervention that optimize health promotion and the prevention, diagnosis, and treatment of disease.  Award: NIH NCATS UL1TR003098. Total award amount including indirect costs: $59,820,410; Project dates: 05/31/2019-04/30/2024

Title: ADalimumab Vs. conventional ImmunoSupprEssion for Uveitis (ADVISE) Trial, Chairman’s Office. Principal Investigator: Douglas A. Jabs, MD, MBA

Role: Research Manager, Chairman’s Office (2019-2023)

Major Goal: The goal of this project is to evaluate the role of the anti-TNF monoclonal antibody adalimumab in the treatment of the uveitides by performing a comparative effectiveness trial versus conventional immunosuppression. This award supports the Chairman’s Office cooperative agreement. Award: NIH NEI UG1EY028096. Total award amount including indirect costs (2019-2023): $682,437. Project dates: 09/30/2018-08/31/2023

Title: Macular Edema Treatment Trials Associate with MUST (META-MUST) Chairman’s Office. Principal Investigator: Douglas A. Jabs, MD, MBA

Role: Research Manager, Chairman’s Office (2020-2022)

Major Goal: The major goal of this project was to address key issues in the treatment of uveitic macular edema with two clinical trials, POINT and MERIT. This award supports the Chairman’s Office cooperative agreement. Award: NIH NEI U10EY024526. Total award amount including indirect costs (2020-2022): $283,358. Project dates: 09/30/2014-07/31/2022

Title: Developing classification criteria for the uveitides (SUN). Principal Investigator: Douglas A. Jabs, MD, MBA. Role: Research Manager (2019-2022)

Major Goal: The goal of this project was to develop internationally accepted, scientifically valid, classification criteria for 25 of the most common uveitic diseases.

Award: NIH NEI R01EY026593. Total award amount including indirect costs (2019-2022): $533,235. Project dates: 04/01/2016-03/31/2022